Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the first quarter ended March 31, 2023, revealing research and development expenses were $7.1 million for the first quarter of 2023, including stock-based compensation of $400,000.
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the fourth quarter and full year ended December 31, 2022, revealing research and development expenses were $21.1 million for full year 2022, including stock-based compensation of $2.0 million.
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue.
What’s The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment,” in the Journal of Neurodevelopmental Disorders.
